imt.ie6h
Protecting against RSV – the role of vaccines for young and old
The success of an ongoing pilot programme offering RSV vaccination to newborn infants provides hope in tackling the ...
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
GlaxoSmithKline (GSK) Gets a Buy from Bernstein
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
The Harvard Crimson16h
Biopharma Giant GSK to Expand Research and Development Footprint in Cambridge
International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
New York, New York-- (Newsfile Corp. - February 19, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) ...